---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145650"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-05-16T23:59:59+00:00"
generated_at: "2026-06-15T00:03:09.641873+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics' COYA 301 shows improved cognition and Treg expansion in Phase 1 AD study

## Summary
- 8 AD patients treated with monthly COYA 301 (low-dose IL-2) showed statistically significant improvement in MMSE scores (p=0.015) during treatment.
- Treg percentage nearly doubled from 4.55% to 8.68% (p=0.0004); suppressive function increased from 46.6% to 79.5% (p=0.003).
- Blood levels of pro-inflammatory cytokines IL-15, CCL2, and CCL11 were significantly lowered after each treatment cycle.
- No serious adverse events; mild injection-site reactions and leukopenia; no patient discontinued the study.

## SEC filing metadata
- accession: 0001193125-23-145650
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312523145650/0001193125-23-145650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312523145650/d471671d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145650
- JSON: https://secwatch.observer/filing/0001193125-23-145650.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.